Beam Therapeutics EV/EBITDA
Что обозначает EV/EBITDA в Beam Therapeutics?
EV/EBITDA Beam Therapeutics Inc. является N/A
Какое определение для EV/EBITDA?
EV / EBITDA - это стоимость предприятия, деленная на прибыль до вычета процентов, налогов, обесценивания и амортизации. При помощи неё измеряется, насколько дорогой является акция, и она более действительна для сравнения компаний, чем для соотношения цены и прибыли. Она измеряет цену (в форме стоимости предприятия), которую инвестор платит в пользу денежного потока компании (в форме EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA компаний в Health Care сектор на NASDAQ по сравнению с Beam Therapeutics
Что делает Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Компании с ev/ebitda похож на Beam Therapeutics
- Castile Resources имеет EV/EBITDA из N/A
- Greenhill & Co Inc имеет EV/EBITDA из N/A
- Cool Link () имеет EV/EBITDA из N/A
- Syntonic имеет EV/EBITDA из N/A
- Merida Minerals Inc имеет EV/EBITDA из N/A
- Golden Meditech имеет EV/EBITDA из N/A
- Beam Therapeutics имеет EV/EBITDA из N/A
- Hummingbird Resources Plc имеет EV/EBITDA из N/A
- Tern Plc имеет EV/EBITDA из N/A
- Magnis Resources имеет EV/EBITDA из N/A
- Fastly Inc имеет EV/EBITDA из N/A
- Soliton имеет EV/EBITDA из N/A
- WeTrade имеет EV/EBITDA из N/A